Supplements

MS Highlights from ACTRIMS/ECTRIMS

Publish date: April 16, 2020

 

This supplement to Neurology Reviews compiles news briefs from the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in Stockholm, Sweden, and the 5th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held in West Palm Beach, Florida.

Click here to read the supplement

Recommended Reading

Age does not appear to affect efficacy of siponimod in secondary progressive MS
MDedge Neurology
Serum GFAP may indicate disease severity in NMOSD
MDedge Neurology
DMT use is common in older patients with MS
MDedge Neurology
Manual dexterity may decline more rapidly in pediatric-onset MS
MDedge Neurology
Teriflunomide increases the likelihood of achieving NEDA in relapsing-remitting MS
MDedge Neurology
Expert says progress in gut-brain research requires an open mind
MDedge Neurology
Clinicians petition government for national quarantine
MDedge Neurology
FDA approves ozanimod for relapsing and secondary progressive forms of MS
MDedge Neurology
FDA removes pregnancy category C warning from certain MS medications
MDedge Neurology
Database will collect data on COVID-19 in patients with MS
MDedge Neurology